BPSR SEC Filings - Organicell Regenerative Medicine Inc- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1557376

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Organicell Regenerative Medicine Inc

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

July 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2025 ZEO SCIENTIFIX, INC. (Exact name o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2025 ZEO SCIENTIFIX, INC. (Exact name o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
July 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2025 ZEO SCIENTIFIX, INC. (Exact name of UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl
July 9, 2025	EX-99.1	ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida Exhibit 99.1 ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida’s New Stem Cell Law FORT LAUDERDALE – July 9, 2025 – ZEO ScientifiX, Inc. (“ZEO” or the “Company”) (OTCQB: ZEOX), a clinical-stage biopharmaceutical company pioneering the development of innovat
June 24, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
June 24, 2025	EX-99.1	2 Exhibit 99.1 ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida’s SB-1768 Law Implementation FORT LAUDERDALE – June 24, 2025 – ZEO ScientifiX, Inc. (“ZEO” or the “Company”) (OTCQB: ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development of innovative biological therapeutics, has announced their upcoming ZEO Masterclass — a physician-led initiat
June 16, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Zeo ScientifiX, Inc.
May 16, 2025	EX-FILING FEES	Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Zeo ScientifiX, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate ($) Amount of Registration Fee ($) Fees to be Pai
May 16, 2025	CORRESP	Zeo ScientifiX, Inc. 3321 College Avenue, Suite 246 Davie, Florida 33314 Zeo ScientifiX, Inc. 3321 College Avenue, Suite 246 Davie, Florida 33314 VIA EDGAR May 16, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549-3629 Attention: Ms. Doris Stacey Gama Ladies and Gentlemen: Re: Zeo ScientifiX, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-286105 Ladie
May 16, 2025	S-1/A	As filed with the Securities and Exchange Commission on May 16, 2025 As filed with the Securities and Exchange Commission on May 16, 2025 File No. 333-286105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of incorporation or organiza
May 12, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emplo
April 16, 2025	S-8	As filed with the Securities and Exchange Commission on April 16, 2025 As filed with the Securities and Exchange Commission on April 16, 2025 Registration No.
April 16, 2025	EX-4.3	Zeo ScientifiX, Inc. 2021 Equity Incentive Plan, as amended. Exhibit 4.3 ZEO SCIENTIFIX, INC. 2021 EQUITY INCENTIVE PLAN (as amended) 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors, and Consultants, and ● to promote the success of the Company’s business. The Plan permits the grant of Incentive S
April 16, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Zeo ScientifiX, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate ($) Amount of Registration Fee ($) Fees to be
April 2, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
April 2, 2025	EX-10.1	Employment Agreement with Ron Borsheim+ Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into effective April 1, 2025 (the “Effective Date”), by and between ZEO SCIENTIFIX, INC., a Nevada corporation (“ZEO” or the “Company”), and RON BORSHEIM (“Executive”). RECITALS WHEREAS, the Company desires to secure the services of Executive, and Executive desires to furnish such services to the Compa
March 27, 2025	DEL AM	Zeo ScientifiX, Inc. 3321 College Avenue, Suite 246 Davie, Florida 33314 Zeo ScientifiX, Inc. 3321 College Avenue, Suite 246 Davie, Florida 33314 VIA EDGAR March 27, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549-3629 Ladies and Gentlemen: Re: Zeo ScientifiX, Inc. Registration Statement on Form S-1 File No. 333-286105 Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-1 (
March 26, 2025	S-1	As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of incorporation or organization) (Primary Standar
March 26, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Zeo ScientifiX, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate ($) Amount of Registration Fee ($) Fees to be
March 17, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Zeo ScientifiX, Inc.
February 18, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
February 18, 2025	EX-99.1	ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer Exhibit 99.1 ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer FORT LAUDERDALE – February 18, 2025 - ZEO ScientifiX, Inc. (“ZEO” or the “Company”) (OTCQB: ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseas
February 11, 2025	EX-99.1	ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community Exhibit 99.1 ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community FORT LAUDERDALE – February 11, 2025 - ZEO ScientifiX, Inc. (“ZEO” or the “Company”) (OTCQB: ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine and the devel
February 11, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
February 10, 2025	EX-10.1	Employment Agreement with Dr. Peter A.M. Everts, Ph.D. dated February 7, 2025 (Filed as an exhibit to the Registrant’s form 8-K filed on February 10, 2025 and incorporated by reference herein) Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into effective February 7, 2025 (the “Effective Date”), by and between ZEO SCIENTIFIX, INC., a Nevada corporation (“ZEO” or the “Company”), and DR. PETER A. M. EVERTS, Ph.D. (“Executive”). RECITALS WHEREAS, the Company desires to secure the services of Executive, and Executive desires to furnish such s
February 10, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
January 29, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000-55008 ZEO SCIENTIFIX, INC. (Exact
January 29, 2025	EX-21.1	Subsidiaries of the Registrant (Filed as an exhibit to the Registrant’s Form 10-K for the fiscal year ended October 31, 2024 filed on January 29, 2025 and incorporated by reference herein) Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Below is a list of subsidiaries of Zeo ScientifiX, Inc. (the “Company”), all of which are wholly owned by the Company, other than noted by an asterisk. Subsidiary Name: Date of Formation: State of Formation: 1. General Surgical Florida, Inc. 1/15/16 FL 2. ClearMind Ventures, LLC (inactive) 8/16/24 DE
January 29, 2025	EX-19.1	Insider Trading Policy (Filed herewith) Exhibit 19.1 ZEO SCIENTIFIX, INC. INSIDER TRADING POLICY 2025 I. Introduction The purpose of this Insider Trading Policy (the “Policy”) is to promote compliance with applicable securities laws by Zeo ScientifiX, Inc. and its subsidiaries (“ZEO” or the “Company”) and all directors, officers and employees of the Company, in order to preserve the reputation and integrity of ZEO as well as that of all
January 29, 2025	EX-3.1	Articles of Incorporation of Zeo ScientifiX, Inc., as amended and restated as of the date of this prospectus (Filed as an exhibit to Form 10-K for the fiscal year ended October 31, 2024 filed on January 29, 2025 and incorporated by reference herein) Exhibit 3.1 Business Number E0448942011 - 9 Filed in the Office of Secretary of State State Of Nevada Filing Number 20244538678 Filed On 12/17/2024 1:14:00 PM Number of Pages 2 4 1 J 01 : 14 : 39p . m . 1 2 1 1 - 2 024 To : Nevada SOS 188s61188n Page : 4of4 2024 - 12 - 1721 : 15:41 GMT Oocusign Envelope ID : 1DCCDCC4 - 0B7A - 4891 - 9038 - 3O883CO2CB2F 18886118813 From : Vcorp Services , LL( EXHIB
December 19, 2024	EX-3.1	Amendment to Certificate of Designation Exhibit 3.1 2024-12-1721:15:41 GMT Page:3of4 FRANCISCO V. AGUILAR secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (ns) 684-5708 Website: www.nvsos.gov Filed in the Office of Secretary of State State Of Nevada Business Number E0448942011-9 Filing Number 20244538678 Filed On 12/17/2024 1:14:00 PM Number of Pages 2 3 1888611ssn LLC Amendment or Withdrawal of NRS 78.1955, 78.
December 19, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
November 22, 2024	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to Form 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation)
November 22, 2024	EX-99.1	Private and Confidential. © 2024 ZEO ScientifiX , Inc. All rights reserved. Exhibit 99.1 Private and Confidential. © 2024 ZEO ScientifiX , Inc. All rights reserved. • G lobal business leader, medical doctor, author, speaker and entrepreneur in the healthcare industry. • T railblazer in regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations in m edicine. • R eceived B.A. from Yale University, M.D. from the Yale School
November 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
November 15, 2024	EX-99.1	P r i v a te a n d Co nfide n tial. © 2 024 Z EO S c i e n tifi X , I n c . All r i gh t s r eserv ed. Exhibit 99.1 P r i v a te a n d Co nfide n tial. © 2 024 Z EO S c i e n tifi X , I n c . All r i gh t s r eserv ed. • G loba l busines s lead e r , medi c a l d o c t o r , a u tho r , spe a k er a n d ent r e p r eneur in th e hea lth c a re indu s t r y . • T r ailb l a z er in r e g ene r a ti v e medi c ine a n d p r e d i c t i v e a n al y ti c s a n d h a s f ocused on tu r n a r o u nd s ,
November 13, 2024	EX-99.1	ZEO SCIENTIFIX AND EXOTROPIN join forces TO LAUNCH a solution to address the growing unmet need for Hair loss The Two Research-Driven Companies To Launch Their New Hair Treatment System At National Conference For Medical Aesthetics Exhibit 99.1 ZEO SCIENTIFIX AND EXOTROPIN join forces TO LAUNCH a solution to address the growing unmet need for Hair loss The Two Research-Driven Companies To Launch Their New Hair Treatment System At National Conference For Medical Aesthetics FT. LAUDERDALE, Florida, November 13, 2024 – ZEO ScientifiX, Inc. (“ZEO” or the “Company”) (OTCQB: ZEOX), a South Florida-based clinical-stage biopharmaceu
November 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 ZEO SCIENTIFIX, INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
October 15, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
October 15, 2024	EX-99.1	ZEO SCIENTIFIX, A LEADING SOUTH FLORIDA BIOTECHNOLOGY COMPANY, Launches Regenerative Medicine Educational SERIES FOR PHYSICIANS Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights Exhibit 99.1 FOR IMMEDIATE RELEASE MEDIA CONTACT: Meieli Sawyer The Weinbach Group 305-668-0070 [email protected] ZEO SCIENTIFIX, A LEADING SOUTH FLORIDA BIOTECHNOLOGY COMPANY, Launches Regenerative Medicine Educational SERIES FOR PHYSICIANS Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights FT. LAUDERDALE, Florida, October 15,
September 30, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR
September 20, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR
September 16, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Zeo ScientifiX, Inc.
August 12, 2024	SC 13G	ZEOX / Zeo ScientifiX, Inc. / Kompothecras Gary - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zeo ScientifiX, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68621D206 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 8, 2024 (Date of Ev
August 7, 2024	8-K	Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
July 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2024 ZEO SCIENTIFIX, INC. (Exact name of UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl
June 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Zeo ScientifiX, Inc.
June 3, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl
April 2, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
March 18, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Zeo ScientifiX, Inc.
March 4, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp
March 4, 2024	EX-99.1	ORGANICELL REGENERATIVE MEDICINE REBRANDING TO ZEO SCIENTIFIX Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol “ZEOX” commencing March 5, 2024 Exhibit 99.1 ORGANICELL REGENERATIVE MEDICINE REBRANDING TO ZEO SCIENTIFIX Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol “ZEOX” commencing March 5, 2024 Fort Lauderdale, Florida – March 4, 2024 – ZEO ScientifiX, Inc. (OTCQB: ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. – OTCQB: OCEL) today reported that the Financial Industry Regulatory
February 26, 2024	EX-3.1	Articles of Amendment to Articles of Incorporation of Organicell Regenerative Medicine, Inc. Exhibit 3.1 Business Entity - Filin g Acknowledgement 02/14/2024 Wor k Orde r Ite m Number: Filing Number: Filing Type: Filin g Date/Time: Filing Page(s): W2024021301622 - 3463314 20243819841 Amendment After Issuance of Stock 2/13/2024 11:01:00 AM 2 Indexed Entity Information: Entity ID: E0448942011 - 9 Entity Status: Active Entity Name: Zeo ScientifiX, Inc. Expiratio n Date : None Commercial Regi
February 26, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2024 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS
January 29, 2024	EX-23.1(A)	Consent of Weinberg & Company P.A. (filed herewith) Exhibit 23.1(a) Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Organicell Regenerative Medicine, Inc. on Form S-8 (File No. 333-260261) of our report dated January 29, 2024, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the consol
January 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000-55008 ORGANICELL REGENERATIVE MED
January 29, 2024	EX-23.1(B)	Consent of Marcum LLP (filed herewith) Exhibit 23.1(b) Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Organicell Regenerative Medicine, Inc. on Form S-8 (File No. 333-260261) of our report dated February 14, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the conso
December 20, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
December 12, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
December 11, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
November 27, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in charter) Nevada 000-55008 47-4180540 (State or other Jurisdiction of Incorporation)
November 27, 2023	EX-3.1	Articles of Amendment to Articles of Incorporation of Organicell Regenerative Medicine, Inc. Exhibit 3.1
November 27, 2023	EX-99.1	Organicell Announces 1-for-200 Reverse Stock Split Exhibit 99.1 Organicell Announces 1-for-200 Reverse Stock Split Fort Lauderdale, Florida – November 27, 2023 – Organicell Regenerative Medicine Inc, (OTCQB: OCEL) (“Organicell” or the “Company”), today announced that it is implementing a 1-for-200 Reverse Split of the Company’s common stock (the “Reverse Split”) effective as of the close of business on November 27, 2023. As a result, every 200 pre
November 14, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
October 19, 2023	PRER14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE
September 28, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
September 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
August 14, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
August 9, 2023	8-K	Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fi
August 1, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
July 26, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fil
July 26, 2023	EX-99.1	Organicell Reports Interim Results of Phase 1/2A Research Program Exhibit 99.1 FOR IMMEDIATE RELEASE Organicell Reports Interim Results of Phase 1/2A Research Program Fort Lauderdale, FL / July 26, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, today reported the results of its Phase 1/2A research program for its biologic therap
July 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 ORGANICELL REGENERATIVE MEDICINE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 29, 2023	EX-99.1	Organicell Welcomes Howard Golub, MD, PhD as its New EVP/CSO Exhibit 99.1 FOR IMMEDIATE RELEASE Organicell Welcomes Howard Golub, MD, PhD as its New EVP/CSO Fort Lauderdale, FL / June 29, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Howard L. Golub, MD, PhD as its new Executive Vi
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 ORGANICELL REGENERATIVE MEDICINE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 21, 2023	EX-99.1	Organicell Welcomes Harry Leider, MD, MBA as its New CEO Exhibit 99.1 FOR IMMEDIATE RELEASE Organicell Welcomes Harry Leider, MD, MBA as its New CEO Fort Lauderdale, FL / June 21, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Harry L. Leider, MD, MBA as its new Chief Executive
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2023 ORGANICELL REGENERATIVE MEDICINE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 16, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
June 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 organicellnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 000-55008 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: April 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Fo
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 ORGANICELL REGENERATIVE MEDICINE, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File
June 6, 2023	EX-10.2	Employment Agreement with Dr. Howard Golub (Filed an exhibit to the Registrant’s Form 8-K filed on June 6, 2023 and incorporated by reference herein) Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into effective June 1, 2023 (the “Effective Date”), by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (“Organicell” or the “Company”), and HOWARD GOLUB, M.D., Ph.D. (“Executive”). RECITALS WHEREAS, the Company desires to secure the services of Executive, and Executive desires
June 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2023 ORGANICELL REGENERATIVE MEDICINE, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File
June 6, 2023	EX-99.1	Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Investor Presentation June 2023 1 Exhibit 99.1 Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Investor Presentation June 2023 1 Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. No Offering of Securities No offer is made by this Investor Presentation (this "Presentation") to invest in Organicell Regenerative Medicine, Inc .. (the "Company") or
June 6, 2023	EX-10.1	Employment Agreement with Dr. Harry Leider Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into effective June 1, 2023 (the “Effective Date”), by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (“Organicell” or the “Company”), and Harry Leider (“Executive”). RECITALS WHEREAS, the Company desires to secure the services of Executive, and Executive desires to furnish su
May 15, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File
May 1, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission Fi
April 21, 2023	EX-16.1	Marcum LLP letter to SEC dated April 21, 2023 Exhibit 16.1 April 21, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Organicell Regenerative Medicine, Inc. under Item 4.01 of its Form 8-K dated April 21, 2023. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Organicell Rege
April 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 ORGANICELL REGENERATIVE MEDICINE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission (IRS Employer of Inc
March 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
March 8, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission (IRS Employer of Inco
March 8, 2023	EX-10.1	Securities Purchase Agreement with AJB Capital Investments dated March 6, 2023 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 6, 2023, by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation, with headquarters located at 3321 College Avenue, Suite 246, Davie, FL 33314 (the “Company”), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its addres
March 8, 2023	EX-10.3	Warrant issued to AJB Capital Investments dated March 6, 2023 Exhibit 10.3 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
March 8, 2023	EX-10.2	Promissory Note made in favor of AJB Capital Investments dated March 6, 2023 Exhibit 10.2 Execution Version NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGIS
February 14, 2023	EX-10.62	Amendment to Albert Mitrani Employment Agreement, dated February 9, 2023 (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2023 and incorporated by reference herein) Exhibit 10.62 ORGANICELL REGENERATIVE MEDICINE, INC. 3321 COLLEGE AVE, SUITE 246 DAVIE, FL 33314 February 9, 2023 Mr. Albert Mitrani Re: February 2023 Amendment to August 2022 Amendment and Employment Agreement (“February 2023 Amendment”) Dear Albert: Reference is made to that certain amendment agreement dated August 19, 2022 (“August 2022 Amendment”) to the Amended and Restated Executive Employme
February 14, 2023	EX-10.61	Amendment to Dr. Maria Ines Mitrani Employment Agreement, dated February 9, 2023 (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2023 and incorporated by reference herein) Exhibit 10.61 ORGANICELL REGENERATIVE MEDICINE, INC. 3321 COLLEGE AVE, SUITE 246 DAVIE, FL 33314 February 9, 2023 Dr. Maria Ines Mitrani Re: February 2023 Amendment to August 2022 Amendment and Employment Agreement (“February 2023 Amendment”) Dear Maria: Reference is made to that certain amendment agreement dated August 19, 2022 (“August 2022 Amendment”) to the Amended and Restated Executive Emplo
February 14, 2023	EX-10.63	Amendment to Ian Bothwell Employment Agreement, dated February 9, 2023 (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2023 and incorporated by reference herein) Exhibit 10.63
February 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000-55008 ORGANICELL REGENERATIVE MED
February 14, 2023	SC 13D/A	BPSR / Biotech Products Services and Research, Inc. / Skycrest Holdings, LLC - SC 13D/A Activist Investment SC 13D/A 1 organicellregensc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Organicell Regenerative Medicine, Inc. (Name of Issuer) common stock $0.001 par value and Series C preferred stock $0.001 par value (Title of Class of Securities) 09074L105 (CUSIP Number) Ian Bothwell, CFO, 4
January 30, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 000-55008 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: October 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form
December 30, 2022	SC 13D	BPSR / Biotech Products Services and Research, Inc. / Skycrest Holdings, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Organicell Regenerative Medicine, Inc. (Name of Issuer) common stock $0.001 par value and Series C preferred stock $0.001 par value (Title of Class of Securities) 09074L105 (CUSIP Number) Ian Bothwell, CFO, 4045 Sheridan Ave., Suite 239, Miami Beach, FL 3
December 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
December 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
November 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
November 21, 2022	EX-99.1	1 Exhibit 99.1 Organicell Regenerative Medicine, Inc. Responds to Recent Promotional Activities Pursuant to OTC Markets Request Davie, Florida ? November 21, 2022 ? Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) (?Organicell? or the ?Company?) has been requested by OTC Markets Group, Inc. (?OTC Markets?) to issue this statement about promotional activity concerning its common stock. On November
November 21, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
October 20, 2022	CORRESP	Organicell Regenerative Medicine, Inc. 7595 SW 33rd Street, Suite 246 Davie, Florida, 33314 Organicell Regenerative Medicine, Inc. 7595 SW 33rd Street, Suite 246 Davie, Florida, 33314 October 20, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 ?F? Street, N.E. Washington, D.C. 20549-3629 Attention: Mr. Gregory Herbers Re: Organicell Regenerative Medicine, Inc. (the Company?) Registration Statement on Form S-1 File No. 333-267563 Ladies and Gentlemen:
October 20, 2022	EX-FILING FEES	Filing Fee Table (Filed herewith) Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Organicell Regenerative Medicine, Inc.
October 20, 2022	S-1/A	As filed with the Securities and Exchange Commission on October 20, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 FORM A-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL RE File No. 333-267563 As filed with the Securities and Exchange Commission on October 20, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 to FORM A-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdi
October 20, 2022	EX-21.1	Subsidiaries of the Registrant (Filed as an exhibit to the Amendment No. l to the Registrant’s Form S-1 Registration Statement filed on October 20, 2022 (File No. 333-267563) and incorporated by reference herein) Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Below is a list of subsidiaries of Organicell Regenerative Medicine, Inc. (the ?Company?), all of which are wholly owned by the Company, other than noted by an asterisk. Subsidiary Name: Date of Formation: State of Formation: 1. General Surgical Florida, Inc. 1/15/16 FL 2. Livin Again Inc. 11/24/20 FL
October 12, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 ORGANICELL REGENERATIVE MEDICIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
October 12, 2022	EX-99.1	Organicell Investor Presentation Dated October 10, 2022* Exhibit 99.1
October 12, 2022	EX-99.1	Organicell Investor Presentation Dated October 10, 2022* Exhibit 99.1
October 12, 2022	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment 1 to Form 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 ORGAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment 1 to Form 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of I
September 27, 2022	EX-10.15	Form of Director Services Agreement (Filed as an exhibit to the Registrant’s Form 8-K filed on September 27, 2022 and incorporated by reference herein) Exhibit 10.15 DIRECTOR SERVICE AGREEMENT THIS DIRECTOR SERVICE AGREEMENT (this ?Agreement?) is made, entered into, and effective as of this day of 2022 (the ?Effective Date?) BY AND BETWEEN: Organicell Regenerative Medicine, Inc. (?Organicell? or the ?Company?), a Nevada corporation. AND: , (the ?Director?) NOW THEREFORE IN CONSIDERATION of the mutual covenants and agreements hereinafter contained
September 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commissio
September 22, 2022	S-1	As filed with the Securities and Exchange Commission on September 22, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. File No. 333- As filed with the Securities and Exchange Commission on September 22, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of incorporation or organiza
September 22, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Organicell Regenerative Medicine Inc.
September 20, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commissio
September 20, 2022	EX-99.1	Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team Exhibit 99.1 Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team MIAMI, FL / ACCESSWIRE / September 20th, 2022 / Organicell Regenerative Medicine, Inc.(OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has recruited a new Chief Operating Officer, C
September 16, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13D to which this exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use Schedule 13D to which this exhibit is attached. Each of them is responsible for the timely f
September 16, 2022	SC 13D	BPSR / Biotech Products Services and Research, Inc. / Greyt Ventures, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ORGANICELL REGENERATIVE MEDICINE, INC. (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 09074L105 (CUSIP Number) Wendy Grey Greyt Ventures LLC 20533 Biscayne Boulevard Suite 648 Aventura FL 33180 (305) 528-6200 (N
September 16, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commissio
September 16, 2022	EX-99.1	Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market Exhibit 99.1 Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market MIAMI, FL / ACCESSWIRE / September 16th 2022 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced today that the Company will expand into the skincare
September 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commissio
September 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
September 13, 2022	SC 13D	BPSR / Biotech Products Services and Research, Inc. / Modi Bhupendra Kumar - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ORGANICELL REGENERATIVE MEDICINE, INC. (Name of Issuer) Shares of Common Stock $0.001 Par Value (Title of Class of Securities) 09074L105 (CUSIP Number) Dr. Bhupendra Kumar Modi 6, Marina Boulevard # 63-18 Singapore 018985 Tel: +65 90072184 Name, Address a
September 9, 2022	EX-99.1	Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment Exhibit 99.1 Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment MIAMI, FL / ACCESSWIRE / September 9th 2022 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, has closed on an additio
September 9, 2022	8-K	Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
September 6, 2022	EX-10.2	Registration Rights Agreement between Organicell and Tysadco, dated September 1, 2022 (Filed as an exhibit to the Registrant’s Form 8-K filed on September 6, 2022 and incorporated by reference herein) Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 1, 2022, by and between ORGANICELL REGENERATIVE MEDICINE INC., a Nevada corporation (the ?Company?), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (together with it permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein s
September 6, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission
September 6, 2022	EX-10.1	Purchase Agreement between Organicell and Tysadco, dated September 1, 2022 (Filed as an exhibit to the Registrant’s Form 8-K filed on September 6, 2022 and incorporated by reference herein) Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of September 1, 2022, is entered into by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to
August 30, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission F
August 30, 2022	EX-99.1	Organicell Regenerative Medicine, Inc. Engages law firm McDermott Will & Emery Exhibit 99.1 Organicell Regenerative Medicine, Inc. Engages law firm McDermott Will & Emery MIAMI, FL / ACCESSWIRE / August 30, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, announced today the broad-based engagement of top international l
August 26, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission F
August 26, 2022	EX-99.1	Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round Exhibit 99.1 Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round MIAMI, FL / ACCESSWIRE / August 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02
August 23, 2022	EX-3.2	Second Amended and Restated Bylaws (as amended effective August 19, 2021) (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF ORGANICELL REGENERATIVE TECHNOLOGIES, INC. (A NEVADA CORPORATION) Amended August 19, 2022 TABLE OF CONTENTS ARTICLE I. OFFICES 1 Section 1.01 Registered. Office. 1 Section 1.02 Other Offices. 1 ARTICLE II. CORPORATE SEAL 1 Section 2.01 Corporate Seal. 1 ARTICLE III. STOCKHOLDERS? MEETINGS 2 Section 3.01 Place of Meetings. 2 Section 3.02 Annual Mee
August 23, 2022	EX-10.9	Amendment to Albert Mitrani Employment Agreement (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.9 ORGANICELL REGENERATIVE MEDICINE, INC. 4045 SHERIDAN AVENUE SUITE 239 MIAMI BEACH, FLORIDA 33140 August 19, 2022 Mr. Albert Mitrani Dear Albert: Reference is made to that certain Amended and Restated Executive Employment Agreement dated June 29, 2020 (the ?Employment Agreement?), by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?) and Albert Mit
August 23, 2022	EX-10.8	Warrant issued to Greyt Ventures LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.8 EXECUTION VERSION THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
August 23, 2022	EX-10.4	Stock Purchase Agreement with Smart Co. Holding Pte. Ltd. (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.4 EXECUTION VERSION STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated effective as of August 19, 2022 (the ?Effective Date?), is made by and among ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?) and SMART CO. HOLDING PTE. LTD., a Singapore corporation (the ?Purchaser?). The Company and the Purchaser are sometimes referred to he
August 23, 2022	EX-10.14	Termination of Management and Consulting Performance Plan Awards (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.14
August 23, 2022	EX-10.6	Consulting Agreement with Greyt Ventures LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.6 EXECUTION VERSION CONSULTING AGREEMENT THIS CORPORATE CONSULTING AGREEMENT, made as of the 19th day of August, 2022 (the ?Effective Date?), is by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?), with its offices at 4045 Sheridan Avenue, Suite 239, Miami, Beach, Florida 33140, and GREYT VENTURES LLC, a Delaware limited liability company (?Consul
August 23, 2022	EX-10.11	Amendment to Ian T. Bothwell Employment Agreement (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.11 ORGANICELL REGENERATIVE MEDICINE, INC. 4045 SHERIDAN AVENUE SUITE 239 MIAMI BEACH, FLORIDA 33140 August 19, 2022 Mr. Ian Bothwell Dear Ian: Reference is made to that certain Amended and Restated Executive Employment Agreement dated June 29, 2020 (the ?Employment Agreement?), by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?) and Ian Bothwell (
August 23, 2022	EX-10.2	Stock Purchase Agreement with Greyt Ventures LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of August 19, 2022 (the ?Effective Date?), is made by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?) and GREYT VENTURES LLC, a Delaware limited liability company (?Greyt? or the ?Purchaser?). The Company and the Purchaser are sometimes referred to herein i
August 23, 2022	EX-10.12	Termination of Consulting Arrangement with Dr. George Shapiro (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.12 ORGANICELL REGENERATIVE MEDICINE, INC. 4045 SHERIDAN AVENUE SUITE 239 MIAMI BEACH, FLORIDA 33140 August 19, 2022 Dr. George Shapiro Dear Dr. Shapiro: Reference is made to that certain consulting arrangement by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?) and Dr. George Shapiro (?Executive?), which was initially approved by the Company?s Boa
August 23, 2022	EX-10.1	Stock Purchase Agreement with Skycrest Holdings, LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of August 19, 2022 (the ?Effective Date?), is made by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?) and SKYCREST HOLDINGS, LLC, a Nevada limited liability company (?Skycrest? or the ?Purchaser?). The Company and the Purchaser are sometimes referred to her
August 23, 2022	EX-10.3	Stock Purchase Agreement with Beyond 100 FZE (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.3 EXECUTION VERSION STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of August 19, 2022 (the ?Effective Date?), is made by and among ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?) and BEYOND 100 FZE, a Dubai corporation (?Beyond 100? or the ?Purchaser?). The Company and the Purchaser are sometimes referred to herein indivi
August 23, 2022	EX-3.1	Certificate of Designation of Series C Non-Convertible Preferred Stock (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 3.1 Exhibit A ORGANICELL REGENERATIVE MEDICINE CERTIFICATE OF DESIGNATION OF SERIES C NON-CONVERTIBLE PREFERRED STOCK Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?), acting pursuant to Chapter 78 of the Nevada Revised Statutes, does hereby submit the following Certificate of Designation of newly created Series C Non-Convertible Preferred Stock (this ?Certifica
August 23, 2022	EX-10.7	Warrant issued to Skycrest Holdings, LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.7 EXECUTION VERSION THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
August 23, 2022	EX-10.10	Amendment to Dr. Maria Ines Mitrani Employment Agreement (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.10 ORGANICELL REGENERATIVE MEDICINE, INC. 4045 SHERIDAN AVENUE SUITE 239 MIAMI BEACH, FLORIDA 33140 August 19, 2022 Dr. Maria Ines Mitrani Dear Maria: Reference is made to that certain Amended and Restated Executive Employment Agreement dated June 29, 2020 (the ?Employment Agreement?), by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?) and Dr. Ma
August 23, 2022	EX-10.5	Consulting Agreement with Skycrest Holdings, LLC (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.5 EXECUTION VERSION CONSULTING AGREEMENT THIS CORPORATE CONSULTING AGREEMENT, made as of the 19th day of August, 2022 (the ?Effective Date?), is by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation (the ?Company?), with its offices at 4045 Sheridan Avenue, Suite 239, Miami, Beach, Florida 33140, and SKYCREST HOLDINGS, LLC, a Nevada limited liability company (?Cons
August 23, 2022	EX-10.13	Form of Warrant to be issued to Ian T. Bothwell and Dr. George Shapiro (Filed as an exhibit to the Registrant’s Form 8-K filed on August 23, 2022 and incorporated by reference herein) Exhibit 10.13 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STAT
August 23, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission F
July 26, 2022	EX-99.1	ORGANICELL ANNOUNCES MATT SINNREICH AS CEO EX-99.1 2 organicellregenrativeex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ORGANICELL ANNOUNCES MATT SINNREICH AS CEO Miami, FL (July 26, 2022) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has ap
July 26, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
July 20, 2022	EX-99.1	ORGANICELL REGENERATIVE MEDICINE, INC. SECURES $4 MILLION IN FUNDING FOR CLINICAL TRIALS AND AGREES TO RESTRUCTURE MANAGEMENT EX-99.1 2 organicellex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ORGANICELL REGENERATIVE MEDICINE, INC. SECURES $4 MILLION IN FUNDING FOR CLINICAL TRIALS AND AGREES TO RESTRUCTURE MANAGEMENT Miami, FL Miami (July 20, 2022)—Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the tr
July 20, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
July 19, 2022	EX-10.2	Binding Letter of Intent with Beyond 100 FZE Exhibit 10.2 July 16, 2022 Organicell Regenerative Medicine, Inc. c/o Mr. Albert Mitrani 4045 Sheridan Avenue Suite 239 Miami, FL 33140 RE: BINDING LETTER OF INTENT (“LOI”) FOR THE PURCHASE OF ORGANICELL STOCK This letter of intent (this “LOI”), when signed where indicated below, shall constitute a binding statement to consummate a transaction by and between Organicell Regenerative Medicine, Inc.,
July 19, 2022	EX-10.1	Binding Letter of Intent with Skycrest Holdings, LLC and Greyt Ventures LLC Exhibit 10.1 July 13, 2022 Organicell Regenerative Medicine, Inc. c/o Mr. Albert Mitrani 4045 Sheridan Avenue Suite 239 Miami, FL 33140 RE: BINDING LETTER OF INTENT (“LOI”) FOR THE PURCHASE OF ORGANICELL STOCK This letter of intent (this “LOI”), when signed where indicated below, shall constitute a binding statement to consummate a transaction by and between Organicell Regenerative Medicine, Inc.,
July 19, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
June 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
March 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
March 11, 2022	CORRESP	Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 March 11, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 “F” Street, N.E. Washington, D.C. 20549-3629 Attention: Ms. Jennifer Angelini Mr. Sergio Chinos Re: Organicell Regenerative Medicine, Inc. (the Company”) Registration Statement on Form S-1 File No. 333-257899 La
March 7, 2022	CORRESP	Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 March 7, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 “F” Street, N.E. Washington, D.C. 20549-3629 Attention: Ms. Jennifer Angelini Mr. Sergio Chinos Re: Organicell Regenerative Medicine, Inc. (the Company”) Amendment No. 1 to Registration Statement on Form S-1 File
March 7, 2022	S-1/A	As filed with the Securities and Exchange Commission on March 7, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MED File No. 333-257999 As filed with the Securities and Exchange Commission on March 7, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of incor
February 14, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission file number: 000-55008 ORGANICELL REGENERATIVE MEDICI
February 14, 2022	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Below is a list of subsidiaries of Organicell Regenerative Medicine, Inc. (the ?Company?), all of which are wholly owned by the Company, other than noted by an asterisk. Subsidiary Name: Date of Formation: State of Formation: 1. ANU Life Sciences, Inc. 8/4/16 FL 2. BD Source and Distribution Corp. 7/23/15 FL 3. Beyond Cells Corp. 7/22/15 FL 4. Ethan New
February 14, 2022	EX-10.42	Securities Purchase Agreement dated January 11, 2022 with AJB Capital Investment (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2022 and incorporated by reference herein) Exhibit 10.42 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of January 11, 2022 (the ?Effective Date?), by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation, with headquarters located at 4045 Sheridan Avenue, Suite 239, Miami, FL 33140 (the ?Company?), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liabil
February 14, 2022	EX-10.43	Promissory Note dated January 11, 2022 made in favor of AJB Capital Investment (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2022 and incorporated by reference herein) Exhibit 10.43 Execution Version NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGI
February 8, 2022	EX-99.1	Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients Exhibit 99.1 Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients PRESS RELEASE Miami, FL Miami (February 8, 2022)?Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has secured its first site to carry out the Organicell Phase I/II Multicen
February 8, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
January 31, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-K 1 organicellnt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 000-55008 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: October 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on
January 13, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2022 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
December 29, 2021	EX-99.1	ORGANICELL REGENERATIVE MEDICINE, INC. PROVIDES UPDATES OF CLINICAL TRIAL ACTIVITIES EX-99.1 2 organicellregex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ORGANICELL REGENERATIVE MEDICINE, INC. PROVIDES UPDATES OF CLINICAL TRIAL ACTIVITIES PRESS RELEASE Miami, FL (December 29, 2021) — Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased to provide its stockholders and the investment
December 29, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
December 15, 2021	S-1/A	As filed with the Securities and Exchange Commission on December 14, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE File No. 333-257999 As filed with the Securities and Exchange Commission on December 14, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of i
December 14, 2021	CORRESP	Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 Organicell Regenerative Medicine, Inc. 4045 Sheridan Avenue, Suite 239 Miami Beach, FL 33140 December 14, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 ?F? Street, N.E. Washington, D.C. 20549-3629 Re: Organicell Regenerative Medicine, Inc. (the Company?) Registration Statement on Form S-1 Filed July 14, 2021 File No. 333-257899 Ladies and Gentlemen: In respo
November 9, 2021	EX-99.1	ORGANICELL REGNERATIVE MEDICINE, INC. UPLIST OF COMMON STOCK TO OTCQB APPROVED Common Stock to trade on OTCQB under the symbol “OCEL” commencing November 9, 2021 Exhibit 99.1 ORGANICELL REGNERATIVE MEDICINE, INC. UPLIST OF COMMON STOCK TO OTCQB APPROVED Common Stock to trade on OTCQB under the symbol ?OCEL? commencing November 9, 2021 PRESS RELEASE Miami, FL (November 9, 2021) ? Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its ap
November 9, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
November 5, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
November 5, 2021	EX-99.1	FINRA APPROVES MARKETPLACE NAME CHANGE TO ORGANICELL REGENERATIVE MEDICINE, INC. AND TRADING SYMBOL CHANGE TO “OCEL” Exhibit 99.1 FINRA APPROVES MARKETPLACE NAME CHANGE TO ORGANICELL REGENERATIVE MEDICINE, INC. AND TRADING SYMBOL CHANGE TO ?OCEL? PRESS RELEASE Miami, FL (November 5, 2021) ? Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial I
November 2, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 Organicell Regenerative Medicine, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or other jurisdiction of incorporatio
November 2, 2021	EX-10.1	Exchange Agreement (Filed as an exhibit to the Registrant’s Form 8-K filed on November 2, 2021 and incorporated by reference herein) Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?) effective as of October 29, 2021 (the ?Effective Date?) by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (the ?Company?) and holders of common stock of the Co
November 1, 2021	S-8	As filed with the Securities and Exchange Commission on October 29, 2021 As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.
November 1, 2021	EX-99.1	2021 Equity Incentive Plan (Filed as an exhibit to the Registrant’s Registration Statement on Form S-8 (File No. 333-26062) and incorporated by reference therein) Exhibit 99.1 ORGANICELL REGENERATIVE MEDICINE, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors, and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incen
October 5, 2021	DEF 14C	SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC.
October 4, 2021	PRER14C	SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No. 2 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No.
September 30, 2021	PRER14C	SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No. 1 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No.
September 24, 2021	PRE 14C	SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, For Use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement ORGANICELL REGERNATIVE MEDICINE, INC.
September 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
August 31, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS E
August 20, 2021	SC 13D/A	BPSR / Biotech Products Services and Research, Inc. / Mitrani Albert - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ORGANICELL REGENERATIVE MEDICINE, INC. (Name of Issuer) Shares of Common Stock $0.001 Par Value (Title of Class of Securities) 09074L105 (CUSIP Number) Albert Mitrani 4045 Sheridan Avenue. Suite 239 Miami Beach, FL 33140 Tel: 888-963-7881 Name, Address a
August 20, 2021	SC 13D/A	BPSR / Biotech Products Services and Research, Inc. / Bothwell Ian T - AMENDMENT NO. 1 Activist Investment SC 13D/A 1 bothwellsc13da.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORGANICELL REGENERATIVE MEDICINE, INC. (Name of Issuer) Shares of Common Stock $0.001 Par Value (Title of Class of Securities) 09074L105 (CUSIP Number) Ian T. Bothwell 4045 Sheridan Avenue. Suite 239 Miami Be
August 20, 2021	SC 13D/A	BPSR / Biotech Products Services and Research, Inc. / Mitrani Maria Ines - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORGANICELL REGENERATIVE MEDICINE, INC. (Name of Issuer) Shares of Common Stock $0.001 Par Value (Title of Class of Securities) 09074L105 (CUSIP Number) Maria Ines Mitrani 4045 Sheridan Avenue. Suite 239 Miami Beach, FL 33140 Tel: 888-963-7881 Name, Addre
August 20, 2021	SC 13G	BPSR / Biotech Products Services and Research, Inc. / Shapiro George Craig - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Organicell Regenerative Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09074L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
July 21, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2021 ORGANICELL REGENERATIVE MEDICINE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
July 21, 2021	EX-99.1	Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers Exhibit 99.1 Organicell Announces FDA Approval Of IND Application For The Use Of Zofin? In COVID-19 Long Haulers PRESS RELEASE Miami, FL (July 21, 2021) ? Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investig
July 14, 2021	S-1	As filed with the Securities and Exchange Commission on July 14, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exa File No. 333- As filed with the Securities and Exchange Commission on July 14, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 47-4180540 (State or other jurisdiction of incorporation or organization)
July 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
June 15, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emp
June 15, 2021	EX-99.1	Organicell Announces Positive Results Of Their Expanded Access Trial For The Treatment Of Mild to Moderate COVID-19 Using ZofinTM Exhibit 99.1 Organicell Announces Positive Results Of Their Expanded Access Trial For The Treatment Of Mild to Moderate COVID-19 Using ZofinTM Miami, FL (June 15th, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the outcome of their expanded access (EA) intermediate s
June 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
June 9, 2021	EX-99.1	Organicell Launches Autologous Blood Derived Platform PPXTM – Patient Pure XTM Exhibit 99.1 Organicell Launches Autologous Blood Derived Platform PPXTM ? Patient Pure XTM Miami, FL (June 9th, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company launched a service platform for their first autologous product called Patient Pure XTM (PPX
June 9, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Empl
May 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Empl
May 19, 2021	EX-99.1	Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan Exhibit 99.1 Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan Miami, FL (May 19, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribu
May 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Empl
May 11, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Empl
May 11, 2021	EX-99.1	Organicell Receives Approval in Pakistan for the use of ZofinTM for Compassionate Grounds for COVID-19 Clinical Trials To Commence Immediately Exhibit 99.1 Organicell Receives Approval in Pakistan for the use of ZofinTM for Compassionate Grounds for COVID-19 Clinical Trials To Commence Immediately Miami, FL (May 11, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its ZofinTM therapy has been approved by Pakis
May 4, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Emplo
May 4, 2021	EX-99.1	Organicell Begins Up-Listing Process On NASDAQ Exchange Exhibit 99.1 Organicell Begins Up-Listing Process On NASDAQ Exchange Miami, FL (May 4, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC.
April 28, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
April 28, 2021	EX-99.1	Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion Exhibit 99.1 Organicell Announces Positive Results Of Initial COVID-19 Zofin? Patient Trial In India And Trial Expansion Miami, FL (April 28, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin? in Ind
April 22, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
April 22, 2021	EX-99.1	Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin™ Exhibit 99.1 Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin? Miami, FL (April 22, 2021) ? Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (F
April 21, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
April 21, 2021	EX-99.1	Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis Exhibit 99.1 Organicell Announces FDA Approval Of IND Application For The Use Of Zofin? In The Treatment Of Osteoarthritis Miami, FL (April 21, 2021) ? Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigati
April 14, 2021	EX-99.1	Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential EX-99.1 2 organicellregex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential Miami, FL (April 14, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today
April 14, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
March 23, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
March 23, 2021	EX-99.1	Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential Exhibit 99.1 Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential Miami, FL (March 23rd, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Coo
March 18, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS Em
March 18, 2021	EX-99.1	‘Frontiers in Medicine’ publishes Organicell’s Case Report Demonstrating the Use of Zofin™ In The Treatment of COVID-19 Patients Exhibit 99.1 ?Frontiers in Medicine? publishes Organicell?s Case Report Demonstrating the Use of Zofin? In The Treatment of COVID-19 Patients Miami, FL (March 18, 2021) - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing t
March 17, 2021	EX-3.1	Certificate of Amendment to the Articles of Incorporation filed with the Secretary of State of Nevada on February 10, 2021, effective February 9, 2021. Exhibit 3.1
March 17, 2021	10-Q	Quarterly Report - 10-Q 10-Q 1 organicell10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:
February 8, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission file number: 000-55008 ORGANICELL REGENERATIVE MEDICI
February 8, 2021	EX-21.1	Subsidiaries of the Registrant (Filed as an exhibit to the Registrant’s Form 10-K filed on February 14, 2022 and incorporated by reference herein) Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Below is a list of subsidiaries of Organicell Regenerative Medicine, Inc. (the “Company”), all of which are wholly owned by the Company, other than noted by an asterisk. Subsidiary Name: Date of Formation: State of Formation: 1. ANU Life Sciences, Inc. 8/4/16 FL 2. BD Source and Distribution Corp. 7/23/15 FL 3. Beyond Cells Corp. 7/22/15 FL 4. Ethan New
January 29, 2021	NT 10-K	- NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 000-55008 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K    ☐ Form 20-F    ☐ Form 11-K    ☐ Form 10-Q    ☐ Form 10-D    ☐ Form N-SAR    ☐ Form N-CSR For Period Ended: October 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐  Transition Report on Form 11-K ☐ Transit
January 28, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
January 28, 2021	EX-99.1	Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) Exhibit 99.1 Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) PRESS RELEASE Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug A
January 19, 2021	DEF 14C	- DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
January 12, 2021	EX-99.1	THE FORGOTTEN ONES. WILL LONG-HAULERS BE THE NEXT PUBLIC HEALTH CRISIS? A LIVE ONLINE DISCUSSION ON COVID-19 LONG-HAULERS HOSTED BY ORGANICELL REGENERATIVE MEDICINE, INC. Exhibit 99.1 THE FORGOTTEN ONES. WILL LONG-HAULERS BE THE NEXT PUBLIC HEALTH CRISIS? A LIVE ONLINE DISCUSSION ON COVID-19 LONG-HAULERS HOSTED BY ORGANICELL REGENERATIVE MEDICINE, INC. Miami Beach, Florida - January 12th, 2021 - Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “Company” or “Organicell”), a clinical-stage biopharmaceutical company dedicated to the development of regenerat
January 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2021 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
January 5, 2021	PRE 14C	- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ORGANICELL REGENERATIVE MEDICINE, INC. (Name of
December 28, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2020 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
December 22, 2020	EX-99.1	ORGANICELL REGENERATIVE MEDICINE, INC. BECOMES CURRENT WITH SEC REPORTING REQUIREMENTS Exhibit 99.1 ORGANICELL REGENERATIVE MEDICINE, INC. BECOMES CURRENT WITH SEC REPORTING REQUIREMENTS Miami, FL (December 22, 2020) - Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Ac
December 22, 2020	8-K	Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2020 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
December 18, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
December 17, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
December 17, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
November 18, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2020 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
November 18, 2020	EX-99.1	Organicell Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for treatment of COVID-19 Exhibit 99.1 Organicell Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for treatment of COVID-19 Miami, FL (November 18, 2020) - Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North loc
November 12, 2020	EX-99.1	Organicell Provides Update on its COVID-19 Clinical Trial Using ZofinTM Exhibit 99.1 Organicell Provides Update on its COVID-19 Clinical Trial Using ZofinTM · Anticipates Phase I/II trial completion by end of year · Anticipates Phase IIb trial to begin in Q1 2021 · Seeks to retain a global contract research organization (“CRO”) Miami, FL (November 12, 2020) - Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to
November 12, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2020 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
October 20, 2020	EX-99.1	Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of ZofinTM for Patients with Heart Failure Exhibit 99.1 Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of ZofinTM for Patients with Heart Failure Miami, FL (October 20, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regener
October 20, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2020 ORGANICELL REGENERATIVE MEDICINE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction (Commission File Number) (IRS
October 16, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
October 16, 2020	EX-10.39	Warrant for the purchase of shares of common stock of Organicell Regenerative Medicine inc. issued to Raymond Zoeller dated May 15, 2020 (Filed as an exhibit to the Registrant’s Form 10-K filed on October 16, 2020 and incorporated by reference herein) Exhibit 10.39 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND APPLICABLE STATE
October 16, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55008 Organicell Regenerative Medicine, Inc.
October 16, 2020	EX-10.38	Warrant for the purchase of shares of common stock of Organicell Regenerative Medicine inc. issued to Ian Bothwell dated February 26, 2020 (Filed as an exhibit to the Registrant’s Form 10-K filed on October 16, 2020 and incorporated by reference herein) Exhibit 10.38 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND APPLICABLE STATE
October 16, 2020	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2019 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission file number: 000-55008 ORGANICEL

BPSR / Organicell Regenerative Medicine Inc - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)